Kodiak Sciences eye drug shows 54% six-month durability
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Kodiak Sciences Inc. reported that Zenkuda (tarcocimab tedromer) and tabirafusp-ted (KSI-501) each met the primary endpoint in the Phase 3 DAYBREAK study in wet age-related macular degeneration, demonstrating non-inferiority in vision gains versus aflibercept at year one. Zenkuda matched and/or exceeded aflibercept’s clinical effect through the loading phase, and 54% of patients achieved six-month durability at year one under strict treat-to-dryness retreatment criteria. Zenkuda’s reported intraocular inflammation rate was 0%, and its cataract adverse event rate was 0.5%, versus 0.9% with aflibercept.
Tabirafusp-ted met the vision primary endpoint (p-value 0.0036) and anatomical key secondary endpoint (p-value <0.0001); its reported intraocular inflammation rate was 0.4% and cataract adverse event rate was 0%, versus 0.9% with aflibercept. Kodiak plans to file a three-indication biologics license application for Zenkuda in the fourth quarter of 2026, supported by five positive Phase 3 studies. The company says the Phase 3 ALTO study of tabirafusp-ted in diabetic macular edema is enrolling and expects KSI-101 Phase 3 PEAK topline data in December 2026.
Positive
- Two DAYBREAK treatments met Phase 3 primary endpoints.
Negative
- None.
Filing Explained
Kodiak plans a
8-K Event Classification
Key Figures
Key Terms
non-inferiority medical
treat-to-dryness medical
best corrected visual acuity medical
biologics license application regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did KOD report from the DAYBREAK study?
When does KOD plan to file Zenkuda’s BLA?
AI-generated analysis. How Rhea-AI works. Not financial advice.